By serially monitoring HBV DNA levels and liver function (ALT), it is now recognized that, viral replication occurs 1-2 weeks before clinical hepatitis flare-up in cancer patients (24, 29, 30) and the inhibitory effect of lamivudine can be achieved after 1-week of administration (31). The gene discussed is GPT; the disease is hepatitis A virus infection.